Trial Profile
Phase II, double-blind, randomized, two-stage, placebo-controlled proof-of-concept study in colorectal cancer patients receiving 5-FU based chemotherapy to assess the efficacy of elsiglutide (ZP1846) administered s.c. in the prevention of chemotherapy induced diarrhea (CID)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2015
Price :
$35
*
At a glance
- Drugs Elsiglutide (Primary)
- Indications Diarrhoea
- Focus Proof of concept; Therapeutic Use
- Sponsors Helsinn Healthcare SA
- 09 Apr 2014 New trial record